EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use

@article{Ingredients2021EUGT,
  title={EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use},
  author={I. Inactive Ingredients},
  journal={Handbook of Pharmaceutical Manufacturing Formulations, Second Edition},
  year={2021}
}
  • I. Ingredients
  • Published 7 January 2021
  • Business
  • Handbook of Pharmaceutical Manufacturing Formulations, Second Edition
This guidance applies to capping operations performed as an aseptic process using sterilized caps or as a “clean process” that is performed outside the aseptic core using clean non-sterilized caps. It is important to note that there may be other additional regional/local area requirements or expectations for capping operations that supersedes the information specified within EU GMP Annex 1 that must be considered (e.g. Irish Medicines Board (IMB) or the Medicines and Healthcare Products… 

Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA)

The findings provide an overview on the submissions and regulatory considerations for generic applications in South Africa, which is useful for FPP manufacturers in the compilation of their dossiers and will assist in accelerating the registration process.

Implementation of a quality assurance system according to GMP and ISO 9001:2008 standard for radiopharmaceutical production in a public research centre

The production of pharmaceuticals is one of the most highly regulated fields in terms of quality. The body of good manufacturing practice (GMP) represents the standard required by law; GMP embraces

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

  • Biology, Medicine
  • 2012
The pharmaceutical, vaccine, and the biotechnology industries have developed and implemented robust quality management systems to ensure the identity, safety, purity and potency of its drug products throughout its manufacture and international distribution channels, thereby eliminating the need for this redundant testing.

Achieving “Zero” Defects for Visible Particles in Injectables

A task force is formed to review and improve particle measurement methods and perform an end-to-end analysis of how particles may enter into parenteral products to lead to more consistent control limits for visible particles and ultimately more consistent supply of high quality injectable products.

Sterilization Validation of Pharmaceuticals

The microbiological quality of drugs is necessary for their efficacy and the safety of the patient s, because microbial contamination of drugs causes immediate adverse effects on patient health in

Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office

Assessment results confirm that IMPs tested in authorized COVID-19 clinical trials are developed in agreement with the same legal requirements for quality, safety, and efficacy as for any other medicinal product in the European Union (EU).

Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review)

Introduction. The article is focused on differences in quality assurance-related obligations and responsibilities between Marketing Authorisation Holders (MAHs) and manufacturing authorisation holder

Good Quality Practice (GQP) in Pharmaceutical Manufacturing: A Handbook

Pharmaceuticals are specialized products because of their characteristics and use and also because of their meticulous regulation. A failure in the quality of a pharmaceutical can put life at risk.

Using Extractables Data of Sterile Filter Components for Scaling Calculations

The applicability of a so-called component approach and a scaling concept to calculate extractables data for sterile polyethersulfone membrane filters and filter capsules of different sizes is shown.

Quality Requirements for Medicinal Cannabis and Respective Products in the European Union - Status Quo.

An EU-wide approach is needed to facilitate free distribution of such products between EU member states in future and to harmonise requirements for quality and GMP, by implementing monographs for cannabis medicinal products in the European Pharmacopoeia.

References

Extension of the International Conference on Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV.

  • W. Grimm
  • Environmental Science
    Drug development and industrial pharmacy
  • 1998
The adjustments that are necessary to extend the stability testing requirements for a registration application within the three areas of the European Union, Japan, and the United States to countries of climatic zones III and IV are described.